The control of reactive oxygen species production by SHP‐1 in oligodendrocytes. Issue 10 (27th April 2015)

• Record Type: Journal Article
• Authors: Gruber, Ross C.; LaRocca, Daria; Minchenberg, Scott B.; Christophi, George P.; Hudson, Chad A.; Ray, Alex K.; Shafit‐Zagardo, Bridget; Massa, Paul T.
• Is Part Of: Glia. Volume 63:Issue 10(2015:Oct.)
• Page Start: 1753
• Page End: 1771
• Publication Date: 2015-04-27
• Subjects: Neuroglia -- Periodicals; Neurology -- Periodicals; 611.0188
• DOI: 10.1002/glia.22842
• Languages: English
• ISSNs: 0894-1491

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>We have previously described reduced myelination and corresponding myelin basic protein (MBP) expression in the central nervous system of Src homology 2 domain‐containing protein tyrosine phosphatase 1 (SHP‐1) deficient motheaten (<italic>me/me</italic>) mice compared with normal littermate controls. Deficiency in myelin and MBP expression in both brains and spinal cords of motheaten mice correlated with reduced MBP mRNA expression levels <italic>in vivo</italic> and in purified oligodendrocytes <italic>in vitro</italic>. Therefore, SHP‐1 activity seems to be a critical regulator of oligodendrocyte gene expression and function. Consistent with this role, this study demonstrates that oligodendrocytes of motheaten mice and SHP‐1‐depleted N20.1 cells produce higher levels of reactive oxygen species (ROS) and exhibit corresponding markers of increased oxidative stress. In agreement with these findings, we demonstrate that increased production of ROS coincides with ROS‐induced signaling pathways known to affect myelin gene expression in oligodendrocytes. Antioxidant treatment of SHP‐1‐deficient oligodendrocytes reversed the pathological changes in these cells, with increased myelin protein gene expression and decreased expression of <italic>nuclear factor (erythroid‐2)‐related factor 2</italic> (Nrf2) responsive gene, heme oxygenase‐1 (<italic>HO‐1</italic>). Furthermore, we demonstrate that SHP‐1 is expressed in human white matter oligodendrocytes, and there is a subset of multiple sclerosis subjects that demonstrate a deficiency of SHP‐1 in normal‐appearing white matter. These studies reveal critical pathways controlled by SHP‐1 in oligodendrocytes that relate to susceptibility of SHP‐1‐deficient mice to both developmental defects in myelination and to inflammatory demyelinating diseases. GLIA 2015;63:1753–1771</p> </abstract>